Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Michael Parini sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $152.93, for a total value of $324,976.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Michael Parini also recently made the following trade(s):

  • On Thursday, August 3rd, Michael Parini sold 2,330 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $155.72, for a total value of $362,827.60.
  • On Wednesday, July 19th, Michael Parini sold 10,829 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $161.00, for a total value of $1,743,469.00.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 154.70 on Tuesday. The company’s 50-day moving average price is $154.24 and its 200-day moving average price is $136.37. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85. The firm has a market cap of $39.00 billion, a price-to-earnings ratio of 148.61 and a beta of 1.73.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.33. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The business had revenue of $544.10 million for the quarter, compared to the consensus estimate of $489.95 million. During the same quarter in the previous year, the company posted $0.24 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 26.1% compared to the same quarter last year. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.62 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) EVP Michael Parini Sells 2,125 Shares” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-evp-michael-parini-sells-2125-shares/1635689.html.

Several equities analysts have weighed in on the company. Raymond James Financial, Inc. raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 target price for the company in a research report on Wednesday, July 19th. J P Morgan Chase & Co set a $175.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Oppenheimer Holdings, Inc. boosted their price objective on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Thursday, July 27th. BMO Capital Markets reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a research report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $167.04.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Intl Fcstone Inc. acquired a new stake in Vertex Pharmaceuticals during the second quarter valued at $752,000. Achmea Investment Management B.V. boosted its position in Vertex Pharmaceuticals by 68.0% during the second quarter. Achmea Investment Management B.V. now owns 8,668 shares of the pharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 3,507 shares during the last quarter. Lord Abbett & CO. LLC boosted its position in Vertex Pharmaceuticals by 88.1% during the second quarter. Lord Abbett & CO. LLC now owns 459,059 shares of the pharmaceutical company’s stock valued at $59,159,000 after purchasing an additional 215,062 shares during the last quarter. USA Financial Portformulas Corp acquired a new stake in Vertex Pharmaceuticals during the second quarter valued at $2,947,000. Finally, RNC Capital Management LLC boosted its position in Vertex Pharmaceuticals by 5.3% during the second quarter. RNC Capital Management LLC now owns 2,978 shares of the pharmaceutical company’s stock valued at $384,000 after purchasing an additional 150 shares during the last quarter. 92.82% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.